Interestingly, combined relationship of the signature and TF expression profiles allowed further delineation of patients into additional risk groups: glioma (EZH2: P < 0.0001; REST: P < 0.0001 and SUZ12: P < 0.0001), clear cell renal cell (EZH2: P < 0.0001), papillary renal cell (EZH2: P = 0.029) and liver (EZH2: P < 0.00057) cancers (Fig. 4b, e). This evidence concerns the gene EZH2 and cancer.